{"schema_version":"secwatch.filing_event.v1","accession":"0001129928-26-000055","form_type":"8-K","ticker":"ONCY","cik":"0001129928","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-09-10T12:17:34+00:00","discovered_at":"2026-09-10T12:20:03.457427+00:00","generated_at":"2026-09-10T12:20:11.288475+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Oncolytics announces positive preclinical results for pelareorep with pan-RAS inhibitor in colorectal cancer","bullets":["Pelareorep + pan-RAS inhibitor reduced tumor growth vs control in RAS-driven colorectal cancer model.","Greatest tumor reductions in RAS inhibitor and combination groups; no antagonism between therapies.","Findings support further evaluation of optimized pelareorep dosing with RAS inhibitors to delay resistance.","Company plans expanded preclinical studies across dosing schedules and RAS-driven tumor models."],"urls":{"canonical":"https://secwatch.observer/filing/0001129928-26-000055","json":"https://secwatch.observer/filing/0001129928-26-000055.json","markdown":"https://secwatch.observer/filing/0001129928-26-000055.md","text":"https://secwatch.observer/filing/0001129928-26-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000055/0001129928-26-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000055/oncy-20260910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-10T12:20:11.288475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}